Trending Stock News

Atlanta Capital Group Has Trimmed Its Altria Group (MO) Holding; 2 Bullish Analysts Covering Vical (VICL)

Among 2 analysts covering Vical (NASDAQ:VICL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vical had 5 analyst reports since July 19, 2016 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, August 9. The rating was reinitiated by H.C. Wainwright with “Buy” on Tuesday, July 19. The rating was maintained by H.C. Wainwright with “Buy” on Monday, June 12. H.C. Wainwright maintained the shares of VICL in report on Tuesday, November 21 with “Buy” rating. The stock of Vical Incorporated (NASDAQ:VICL) has “Buy” rating given on Monday, June 12 by Rodman \u0026 Renshaw. See Vical Incorporated (NASDAQ:VICL) latest ratings:

21/11/2017 Broker: H.C. Wainwright Rating: Buy Maintain
09/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.0000 Maintain

Atlanta Capital Group decreased Altria Group Inc (MO) stake by 18.79% reported in 2017Q2 SEC filing. Atlanta Capital Group sold 8,896 shares as Altria Group Inc (MO)’s stock declined 2.84%. The Atlanta Capital Group holds 38,440 shares with $2.86M value, down from 47,336 last quarter. Altria Group Inc now has $137.02 billion valuation. The stock increased 0.22% or $0.155 during the last trading session, reaching $71.805. About 3.99 million shares traded. Altria Group, Inc. (NYSE:MO) has risen 11.92% since December 12, 2016 and is uptrending. It has underperformed by 4.78% the S&P500.

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company has market cap of $33.29 million. It is developing various DNA vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy. It currently has negative earnings. The firm also engages in contract manufacturing of plasmid investigational products for various clients.

The stock decreased 2.19% or $0.04 during the last trading session, reaching $1.79. About 65,117 shares traded. Vical Incorporated (NASDAQ:VICL) has declined 38.65% since December 12, 2016 and is downtrending. It has underperformed by 55.35% the S&P500.

Analysts await Altria Group, Inc. (NYSE:MO) to report earnings on February, 7. They expect $0.81 earnings per share, up 19.12% or $0.13 from last year’s $0.68 per share. MO’s profit will be $1.55B for 22.16 P/E if the $0.81 EPS becomes a reality. After $0.90 actual earnings per share reported by Altria Group, Inc. for the previous quarter, Wall Street now forecasts -10.00% negative EPS growth.

Among 19 analysts covering Altria Group Inc. (NYSE:MO), 13 have Buy rating, 0 Sell and 6 Hold. Therefore 68% are positive. Altria Group Inc. had 51 analyst reports since July 31, 2015 according to SRatingsIntel. Piper Jaffray maintained Altria Group, Inc. (NYSE:MO) on Thursday, July 27 with “Buy” rating. Jefferies maintained Altria Group, Inc. (NYSE:MO) rating on Monday, July 17. Jefferies has “Hold” rating and $70 target. As per Friday, February 3, the company rating was downgraded by Berenberg. The company was maintained on Monday, July 31 by Wells Fargo. Stifel Nicolaus maintained Altria Group, Inc. (NYSE:MO) on Monday, July 17 with “Buy” rating. The firm has “Equal Weight” rating given on Thursday, March 30 by Barclays Capital. On Monday, June 5 the stock rating was maintained by Jefferies with “Hold”. The rating was maintained by Cowen & Co on Friday, July 7 with “Hold”. The company was maintained on Thursday, September 15 by CLSA. The rating was maintained by Wells Fargo with “Buy” on Friday, August 11.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *